Fierce Biotech April 18, 2024
Max Bayer

The number of biopharma M&A deals more than doubled in the first quarter of 2024 compared to the same period a year ago, exemplifying a top exit route for pre-commercial companies vying for validation and attention.

A new report from Leerink Partners released this week tallied 13 biopharma M&A deals in the first quarter of 2024 compared to six in the first quarter of 2023. There were 47 deals in the last twelve months through March 2024, compared to 42 through March 2023.

The Leerink M&A team described persistent Big Pharma interest specifically in biotechs focusing on new cancer drugs, namely radiopharmaceutical and antibody-drug conjugate (ADC) makers. AstraZeneca made two deals in the oncology sphere while Merck offered bait...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Survey / Study, Trends
How digital health companies are capitalizing on the GLP-1 boom
Journalists Zero In on Bird Flu and Weight Loss Drugs
GLP-1 Agonists in Adolescents and Young Adults; Benefits of Cancer Drug Trials
Chasing the alchemy of trial diversity with a mix of culture change and practical mechanics
Ozempic Drug Semaglutide Could Protect Kidneys, Study Finds

Share This Article